These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 20379117

  • 1. [Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab].
    Mimura N, Kojima H, Tsujimura H, Ise M, Sakai C, Fukai K, Yokosuka O, Kumagai K.
    Rinsho Ketsueki; 2010 Mar; 51(3):213-5. PubMed ID: 20379117
    [Abstract] [Full Text] [Related]

  • 2. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
    Mimura N, Tsujimura H, Ise M, Sakai C, Kojima H, Fukai K, Yokosuka O, Takagi T, Kumagai K.
    Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
    [Abstract] [Full Text] [Related]

  • 3. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM.
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [Abstract] [Full Text] [Related]

  • 4. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK.
    J Clin Oncol; 2009 Feb 01; 27(4):605-11. PubMed ID: 19075267
    [Abstract] [Full Text] [Related]

  • 5. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.
    Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, Takeuchi M.
    Cancer; 2010 Oct 15; 116(20):4769-76. PubMed ID: 20597091
    [Abstract] [Full Text] [Related]

  • 6. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS.
    Eur J Cancer; 2013 Nov 15; 49(16):3486-96. PubMed ID: 23910494
    [Abstract] [Full Text] [Related]

  • 7. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST.
    Ann Hematol; 2011 Oct 15; 90(10):1219-23. PubMed ID: 21520001
    [Abstract] [Full Text] [Related]

  • 8. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D, Cao J, Hong X, Li J, Wang J, Chen F, Wang C, Zou S.
    Eur J Haematol; 2010 Sep 15; 85(3):243-50. PubMed ID: 20491883
    [Abstract] [Full Text] [Related]

  • 9. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM, Huang YH, Lee PC, Lin HC, Lee SD.
    J Clin Gastroenterol; 2009 Sep 15; 43(5):496-8. PubMed ID: 19247200
    [Abstract] [Full Text] [Related]

  • 10. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients.
    Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY.
    Ann Hematol; 2010 Mar 15; 89(3):255-62. PubMed ID: 19697028
    [Abstract] [Full Text] [Related]

  • 11. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
    Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N.
    J Clin Oncol; 2010 Dec 01; 28(34):5097-100. PubMed ID: 20837949
    [Abstract] [Full Text] [Related]

  • 12. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
    Borentain P, Colson P, Coso D, Bories E, Charbonnier A, Stoppa AM, Auran T, Loundou A, Motte A, Ressiot E, Norguet E, Chabannon C, Bouabdallah R, Tamalet C, Gérolami R.
    J Viral Hepat; 2010 Nov 01; 17(11):807-15. PubMed ID: 20002298
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
    Alexopoulou A, Theodorou M, Dourakis SP, Karayiannis P, Sagkana E, Papanikolopoulos K, Archimandritis AJ.
    J Viral Hepat; 2006 Sep 01; 13(9):591-6. PubMed ID: 16907845
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.